Your Guide to Understanding Clinical Trials and Your Options

Changing the story of cancer care requires a combination of leading-edge science and personalized care. Ignyta’s clinical trials are designed to be accessible to the widest variety of patients, whether by geographic location or cancer type. Our individualized approach to cancer trials and our unique Rx/Dx capability allow us to streamline the patient testing and enrollment process and ensure that all eligible patients have access to an Ignyta clinical trial.

How Ignyta Cares for Patients

Even in the best of circumstances, it can be hard for patients to find, research, and access trials related to their disease. Below are some of the obstacles that block patients from enrolling in potentially beneficial clinical trials and information about how Ignyta ensures that every eligible patient has access to an Ignyta clinical trial:

Ignyta addresses many common patient concerns about participating in cancer clinical trials With an ever-expanding network of clinical trials sites, chances are there's an Ignyta clinical trials site near you. Ignyta's streamlined clinical trials process means clear communication about results, eligibility, and updates on the trial. Ignyta works to provide you and your oncologist with all relevant information to make the best decision for you.

How Do I Participate in an Ignyta Clinical Trial

Learn about Ignyta's STARTRK-2 clinical trial and find out what types of cancer are eligible at Have your doctor contact Ignyta's molecular diagnostics lab to find out if your cancer is a match for an Ignyta clinical trial Review your diagnostic test with your doctor and decide if participation in an Ignyta clinical trial is right for you Find a clinical trial site near you and get connected to complete the screening process. See the list at

How Ignyta’s “Basket” Clinical Trials Are Different

Ignyta’s clinical trials are designed to pinpoint the patients most likely to benefit from Ignyta’s precision medicines. In order to do that, our trials are structured a little differently. In medical terminology, our trials are referred to as “basket trials.” Basket trials allow us to focus on the specific cause of cancer, regardless of the type or location of cancer. As long as the cancer is caused by the molecular alteration that our drug targets (in the case of entrectinib, we target NTRK, ROS1, and ALK gene fusions), we can enroll patients, whether they have lung cancer, thyroid cancer, or any other type of solid tumor cancer with that alteration.

Image showing how Ignyta's basket clinical trials focus on a specific genetic alteration instead of a specific cancer type
Ignyta's basket clinical trials focus on a specific genetic alteration instead of a specific cancer type

In this way, Ignyta ensures that we’re opening our trials to the widest possible range of patients, with the largest number of cancer types. It’s yet another way that Ignyta’s precision medicine approach means better accessibility to trials and more options for patients with certain forms of late-stage cancer.

Current Ignyta Cancer Clinical Trials

  • STARTRK-2Ignyta’s STARTRK-2 clinical trial is actively recruiting NTRK1, NTRK2, NTRK3, ROS1, and ALK positive patients. For more information, visit
  • RXDX-105-01 – Ignyta’s RXDX-105-01 clinical study targets cancers with RET and BRAF fusions in patients with advanced solid tumors. For more information, visit

Patient Resources

For more information on cancer treatment for patients and caregivers, including a glossary of terms, patient advocacy organizations and other helpful links, visit Ignyta’s cancer patient resources page.

Patient Stories

At Ignyta, we are humbled by the patients who choose to partner with us in these trials, and we present their stories as a tribute and a promise to keep working, keep fighting, until we reach our goals. Read our patient stories.